Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis B Cortot

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 15, 2024
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU studyMarion Ferreira, Aurélie Swalduz, Laurent Greillier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2021
First-Line Afatinib plus Cetuximab for <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung StudyAlexis B Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohortSimon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
JAMA Oncology|June 4, 2023
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical TrialJulien Mazieres, Paul K Paik, Marina C Garassino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialJulien Mazieres, Fabrice Barlesi, Isabelle Rouquette, et al.
Molecular Oncology|February 17, 2023
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in miceMarie Fernandes, Brynna Hoggard, Philippe Jamme, et al.
Lancet (London, England)|January 28, 2017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyJean-Charles Soria, Daniel S W Tan, Rita Chiari, et al.
Frontiers in Oncology|November 16, 2020
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable <i>KRAS</i> Mutation Who Failed Prior Platinum-Based Therapy: JUNIPERJonathan W Goldman, Julien Mazieres, Fabrice Barlesi, et al.
Clinical Lung Cancer|November 5, 2025
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 StudiesBob T Li, Leena Gandhi, Vignesh Ravichandran, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Lung Cancer (Amsterdam, Netherlands)|September 15, 2024
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU studyMarion Ferreira, Aurélie Swalduz, Laurent Greillier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2021
First-Line Afatinib plus Cetuximab for <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung StudyAlexis B Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohortSimon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
JAMA Oncology|June 4, 2023
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical TrialJulien Mazieres, Paul K Paik, Marina C Garassino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialJulien Mazieres, Fabrice Barlesi, Isabelle Rouquette, et al.
Molecular Oncology|February 17, 2023
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in miceMarie Fernandes, Brynna Hoggard, Philippe Jamme, et al.
Lancet (London, England)|January 28, 2017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyJean-Charles Soria, Daniel S W Tan, Rita Chiari, et al.
Frontiers in Oncology|November 16, 2020
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable <i>KRAS</i> Mutation Who Failed Prior Platinum-Based Therapy: JUNIPERJonathan W Goldman, Julien Mazieres, Fabrice Barlesi, et al.
Clinical Lung Cancer|November 5, 2025
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 StudiesBob T Li, Leena Gandhi, Vignesh Ravichandran, et al.
Pageof 8